Drug Pipeline

EYLEA® (aflibercept) Injection 2 mg (0.05mL) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
2
Phase 3
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-02 NCT06864988
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular…		 Trial sites reduced: 100 -> 95 locations
Active Studies by Phase
Phase 3
2
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07064759 Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization… Neovascular Age-Related Macular Degeneration (nAMD) Recruiting
NCT06864988 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular… Macular Neovascularization Secondary to Age-Related Macular Degeneration Active, Not Recruiting
Phase 2
NCT07557121 Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular… Neovascular (Wet) Age-Related Macular Degeneration Not Yet Recruiting
Sponsors Running EYLEA® (aflibercept) Injection 2 mg (0.05mL) Trials
4D Molecular Therapeutics (2) AiViva BioPharma, Inc. (1)
Get alerts when EYLEA® (aflibercept) Injection 2 mg (0.05mL) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free